PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Sauce Shop is a craft condiment brand which offers customers a variety of fresh-tasting, innovative and punchy flavoured sauces. The company's products have received 2000 5-star reviews on their online shop, and total revenue is over £340k (EBITDA -£13.5k - July 2019). The revenue growth of the company is over 100% YOY. The brand is now stocked in Sainsbury's, Harvey Nichols, Whole Foods Market and many independent food retailers across the UK. Its Tomato Ketchup won a 2-star Great Taste Award. The company will use the funds to expand operational capacity, grow its team and to facilitate a move in premises to ensure that they can continue to meet demand.
days to go:
Expired
investment:
£254,270
Troubadour is a London-based menswear brand specialising in designing minimalist bags & accessories by combining performance design with a clean & modern aesthetic feel. The company has delivered its products to 60+ wholesalers. It is backed by Pembroke VCT, a luxury-focused venture capital firm based in London. Troubadour is planning to work with non-traditional retailers including Ritz Carlton, Four Seasons, and Equinox. It has also collaborated with many world-renowned brands such as British tailors 'Thom Sweeney' and British essentials brand 'Sunspel' that is famous for clothing James Bond. The company has also been a case study for classes at the Harvard Business School. With the investment, the company will support sales growth to its customers and retail partners and also fund working capital requirements from its forecast growth plan.
days to go:
Expired
investment:
£621,240
Maven Leisure Limited, or Maven, is being established by the current owners and senior management of ETM Group Limited, which operates 13 premium bars, pubs and restaurants in Central London including, rooftop bar Aviary, The Botanist Sloane Square, premium sports bars Greenwood, Westwood and Redwood and its brew and sports pub, Long Arm Pub and Brewery. Maven's founders aim to take advantage of favourable market conditions and raise third-party capital to fund anticipated growth over the next three to five years. ETM asserts that it has grown from a single site to a business turning over c.£35 million and generating c.£3.2 million EBITDA with no external equity funding since its formation in 2013. It aspires to take Maven towards profitability. Maven cites data stating that sector experts predict a rapid return to previous levels of business in the hospitality sector once the Covid-19 lockdown is relaxed. It aims to capitalise on this sentiment and use the investment to grow its profitability across different verticals.
days to go:
Expired
investment:
Withheld
PonchoPay aims to change the way parents pay for childcare and access the government funding they're entitled to.
Hundreds of millions of pounds of government support available to parents is going unspent each year due to poor awareness, clunky processes and a low adoption of technology. PonchoPay is making it easy for any source of funding to be aggregated at point of checkout, saving parents money and saving childcare providers a significant amount of time in the process.
Using Poncho Pay's intelligent automation engine, our vision is for parents to be able to quickly access and use this funding across all childcare providers that are registered to receive them nationwide.
As we build our prominent role in the payment journey, PonchoPay will be well positioned to offer additional services in future to parents and childcare providers alike. Growth capital and insurance solutions for childcare providers, Buy Now Pay Later for parents and AI-powered booking curation tools are a handful of additional revenue sources that we plan to explore in the future.
days to go:
Expired
investment:
£405,860
PathCloud aims to assemble the global clinical diagnostics resources and data and make them safely available and helpful. The company has created and tested one of the first scalable clinical diagnostics management platforms. It currently has 20,000 clinicians partner networks and 92 registered clinicians. Additionally, it has a network across 48 counties, has over 100 providers, over 3500 diagnostics tests registered and over 10,000 patients by partner telemedicine networks. These funds will be used to gain a significant portion of diagnostics supplier agreements towards the scaling objective, increase efforts towards the international markets and NHS and pursue telemedicine networks.
days to go:
Expired
investment:
£81,720
